<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03645525</url>
  </required_header>
  <id_info>
    <org_study_id>EKYYIUMTB</org_study_id>
    <nct_id>NCT03645525</nct_id>
  </id_info>
  <brief_title>Intratracheal Umbilical Cord-derived Mesenchymal Stem Cell for the Treatment of Bronchopulmonary Dysplasia (BPD)</brief_title>
  <acronym>IUMTB</acronym>
  <official_title>Intratracheal Umbilical Cord-derived Mesenchymal Stem Cell for the Treatment of Bronchopulmonary Dysplasia (BPD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Hospital of Fudan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Children's Hospital of Fudan University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Umbilical Cord-derived Mesenchymal stem cell has been proven effective in the experimental
      bronchopulmonary dysplasia (BPD).A multi-center study was designed to evaluate the safety and
      efficacy of the cellular therapy in extremely preterm infants at high risk for BPD.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Brochopulmonary dysplasia is a severe chronic lung disease in extremely preterm infants. The
      morbidity of BPD is increasing in CHINA. The preventive and therapy methods of BPD are still
      lacking.

      Umbilical Cord-derived Mesenchymal stem cell has been proven effective in the experimental
      bronchopulmonary dysplasia (BPD). A multi-center study was designed to evaluate the safety
      and efficacy of the cellular therapy in extremely preterm infants at high risk for BPD.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 1, 2019</start_date>
  <completion_date type="Anticipated">April 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">October 30, 2020</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Oxygen requirement 3 days after transplantation</measure>
    <time_frame>3 days</time_frame>
    <description>Temporal profiles of the fraction of inspiration oxygen 3 days after transplantation, the tolerable required oxygen ，which is the minimum fraction of inspiration oxygen in which the participants has a stable SpO2 (90%-95%), measured in %</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Oxygen requirement 7 days after transplantation</measure>
    <time_frame>7 days</time_frame>
    <description>Temporal profiles of the fraction of inspiration oxygen 7 days after transplantation, the tolerable required oxygen ，which is the minimum fraction of inspiration oxygen in which the participants has a stable SpO2 (90%-95%), measured in %</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of ventilator dependence</measure>
    <time_frame>up to 36 weeks PMA</time_frame>
    <description>The duration from transplantation to weaning from ventilator</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of severe BPD</measure>
    <time_frame>up to 36 weeks PMA</time_frame>
    <description>percentage of participants with severe BPD ,diagnosed at 36 weeks PMA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival rate</measure>
    <time_frame>up to 36 weeks PMA</time_frame>
    <description>Percentage of participants who survived up to 36 weeks PMA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Temperature</measure>
    <time_frame>3 days</time_frame>
    <description>Temporal profiles of temperature</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart rate</measure>
    <time_frame>3 days</time_frame>
    <description>Temporal profiles of heart rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Respiratory rate</measure>
    <time_frame>3 days</time_frame>
    <description>Temporal profiles of respiratory rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of CPAP treatment</measure>
    <time_frame>up to 36 weeks PMA</time_frame>
    <description>Duration of CPAP treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants treated with steroids for weaning from ventilator</measure>
    <time_frame>up to 36 weeks PMA</time_frame>
    <description>Percentage of participants treated with steroids for weaning from ventilator</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Growth velocity (Z-score)</measure>
    <time_frame>up to 36 weeks PMA</time_frame>
    <description>percentile for body weight, height, and head circumference</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>bronohoalveolar lavage (BAL) cytokine level</measure>
    <time_frame>7 days</time_frame>
    <description>BAL were collected 7 days after transplantation for cytokine (IL-6，IL-8，TNF-α，TGF-β,VEGF,HGF) level examination, measured in pg/ml</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The severity of BPD in X-ray patterns</measure>
    <time_frame>7 days</time_frame>
    <description>A chest X-ray was performed in participants before and after transplantation. The severity of BPD (mild，moderate，severe) was assessed by a single radiographic doctor who is blind about randomization</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Bronchopulmonary Dysplasia</condition>
  <arm_group>
    <arm_group_label>Mesenchymal stem cell</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Human Umbilical Cord-derived Mesenchymal stem cell in the saline</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>saline without mesenchymal stem cell</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Human Umbilical Cord-derived Mesenchymal stem cell</intervention_name>
    <description>The Human Umbilical Cord-derived Mesenchymal stem cells suspension (2×10^7/kg per KG of the infant 's weight ) will be instilled once through a catheter into the infant' s endotracheal tube</description>
    <arm_group_label>Mesenchymal stem cell</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>saline</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Extremely preterm infants who remain on mechanic ventilator after 2 weeks of postnatal
             age

          -  Extremely preterm infants with a X-ray sign of BPD after 2 weeks of postnatal age

        Exclusion Criteria:

          -  Patients with severe congenital diseases

          -  Patients with IVH more than 3 grade

          -  Patients with severe sepsis

          -  Patients with active pulmonary hemorrhage
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>3 Weeks</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chen Chao, PhD,MD</last_name>
    <role>Study Director</role>
    <affiliation>Chiledren's Hospital of Fudan University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Chen Chao, PhD,MD</last_name>
    <phone>86-13681709999</phone>
    <email>chen6010@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Obstetrics and Gynecology Hospital of Fudan University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200011</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lu Chengqiu</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Fudan University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>201102</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chao Chen, PhD, MD</last_name>
      <phone>13681709999</phone>
    </contact>
    <investigator>
      <last_name>Chengqiu Lu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jie Lin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shanghai First Maternity and Infant Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>201204</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jiangqin Liu</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>August 16, 2018</study_first_submitted>
  <study_first_submitted_qc>August 23, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 24, 2018</study_first_posted>
  <last_update_submitted>February 13, 2020</last_update_submitted>
  <last_update_submitted_qc>February 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Bronchopulmonary Dysplasia</keyword>
  <keyword>Mesenchymal stem cell</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bronchopulmonary Dysplasia</mesh_term>
    <mesh_term>Hyperplasia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

